이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MedX Health 관리

관리 기준 확인 2/4

MedX Health's CEO는 Stephen Lockyer, May2023 에 임명되었습니다 의 임기는 1.08 년입니다. 는 CA$ 7.51K 가치에 해당하는 회사 주식의 0.041% 직접 소유합니다. 7.51K. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 6.1 년입니다.

주요 정보

Stephen Lockyer

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.2yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	6.2yrs

최근 관리 업데이트

Recent updates

CEO

Stephen Lockyer

1.2yrs

테뉴어

Mr. Stephen Lockyer serves as Director of MedX Health Corp since April 12, 2023 and serves as its Chief Executive Officer since May 11, 2023. He co founded Cornwallis Financial Corporation and serves as it...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christopher Freeman	Corporate Secretary & Acting CFO	2.3yrs	CA$14.93k	데이터 없음
Michael Druhan	President of Dermatological Services & Products	3.8yrs	CA$273.52k	데이터 없음
Stephen Lockyer	CEO & Director	1.2yrs	데이터 없음	0.041% CA$ 7.0k
Scott Naughton	Managing Director of US Operations	7.6yrs	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

경험이 풍부한 관리: MDX 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Stephen Lockyer	CEO & Director	1.3yrs	데이터 없음	0.041% CA$ 7.0k
David Henniger	Independent Vice Chairman	22.7yrs	데이터 없음	1.35% CA$ 230.9k
Kenneth McKay	Independent Chairman	22.7yrs	데이터 없음	0.33% CA$ 56.4k
Daniel Siegel	Member of Medical Advisory Board	6.2yrs	데이터 없음	데이터 없음
Dennis Reich	Member of Medical Advisory Board	7.4yrs	데이터 없음	데이터 없음
Trevor Champagne	Chairman of Medical Advisory Board	5.9yrs	데이터 없음	데이터 없음
Joe Walls	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Per Hall	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Edmund Ho	Independent Director	1.3yrs	데이터 없음	4.66% CA$ 795.1k

6.2yrs

평균 재임 기간

73yo

평균 연령

경험이 풍부한 이사회: MDX 의 이사회는 경험(평균 재직 기간 6.1 년)으로 간주됩니다.

MedX Health 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CEO & Director exercised options to buy CA$1.3m worth of stock.

MedX Health Corp Announces Resignation of Naman Damaghlatrous as Director

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

First quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.007 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.023 loss per share (vs CA$0.028 loss in FY 2022)

MedX Health Corp announced that it expects to receive CAD 2 million in funding

New major risk - Share price stability

Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.006 loss in 3Q 2022)

CEO & Director exercised options to buy CA$1.3m worth of stock.

MedX Health Corp announced that it has received CAD 1.02 million in funding

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2022)

New major risk - Share price stability

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 1Q 2022)

MedX Health Corp Announces Resignation of Naman Damaghlatrous as Director

Full year 2022 earnings released: CA$0.028 loss per share (vs CA$0.03 loss in FY 2021)

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding from Forest Lane Holdings Limited

Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 3Q 2021)

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding from Forest Lane Holdings Limited

Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021)

MedX Health Corp announced that it expects to receive CAD 4 million in funding

Full year 2021 earnings released: CA$0.03 loss per share (vs CA$0.019 loss in FY 2020)

MedX Health Corp announced that it expects to receive CAD 4 million in funding

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Chairman of the Board Robert von der Porten has left the company

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 2Q 2020)

COO & MD of Light Therapy Products recently sold CA$53k worth of stock

First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 1Q 2020)

MedX Health Corp announced that it expects to receive CAD 2.5 million in funding

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.023 loss in FY 2019)

MedX Health Corp. Announces Retirement of Board Members

EMPOWER CLINICS INC. and MedX Health Corporation Announce Memorandum of Understanding to Pilot MedX's Leading-Edge DermSecure Screening Platform At Two Select Empower Clinics Locations in Ontario

MedX Health Corp. Announces the Appointment of Paul Karam as Sales and Marketing Director for Europe, Middle East, Africa (EMEA)

New 90-day high: CA$0.24

MedX Health Corp announced that it expects to receive CAD 4 million in funding

MedX Health Corporation Appoints Trevor Champagne as Chair Medical Advisory Board

Medx Health Corp. Announces the Rollout of DermSecure in the Netherlands

Third quarter 2020 earnings released: CA$0.006 loss per share

MedX Health Corp Announces Board Changes

Medx Health Corp. Appoints Anthony Milonas and Wayne Cockburn as Directors

First half earnings released

MedX Health Corp. Announces Management Appointments

MedX Health Corp announced that it expects to receive CAD 2 million in funding

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령